Stock AGL AGILON HEALTH, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus agilon health, inc.

Equities

AGL

US00857U1079

Market Closed - Nyse
Other stock markets
 21:00:02 30/04/2024 BST 		5-day change 1st Jan Change
5.5 USD +7.21% Intraday chart for agilon health, inc. +3.00% -56.18%
04-22 Citigroup Starts agilon health With Neutral Rating, $6 Price Target MT
03-06 Barclays Initiates Agilon Health With Underweight Rating, Price Target is $5 MT

Evolution of the average Target Price on agilon health, inc.

Price target over the last 5 years

History of analyst recommendation changes

4c03.A8FVYGbHL1zSL272ARwcOwIm-9BPQ6DhPBvnUy3d60A.O7djKQCsSTeaQzusY1pmdC8esrh-GurQd1awIR6Rjwx2hCc5DJ93EbFfNw~23fc0da80f573ece7d6445a516d0d335

Analyst Recommendations on agilon health, inc.

Citigroup Starts agilon health With Neutral Rating, $6 Price Target MT
Barclays Initiates Agilon Health With Underweight Rating, Price Target is $5 MT
Deutsche Bank Cuts Agilon Health's Price Target to $8 From $10, Maintains Hold Rating MT
Truist Securities Cuts Price Target on Agilon Health to $7.50 From $10, Maintains Hold Rating MT
RBC Cuts Price Target on Agilon Health to $8 From $11, Says Near Term 'Could Remain Choppy,' Keeps Outperform Rating MT
TD Cowen Downgrades Agilon Health to Market Perform From Outperform MT
Deutsche Bank Adjusts Price Target on Agilon Health to $10 From $12, Maintains Hold Rating MT
Wolfe Research Downgrades Agilon Health to Peer Perform From Outperform MT
JPMorgan Downgrades Agilon Health to Neutral From Overweight, Cuts Price Target to $9 From $17 MT
Goldman Sachs Downgrades Agilon Health to Neutral From Buy, Cuts Price Target to $14 From $22 MT
JMP Securities Initiates Agilon Health With Market Outperform Rating, Price Target is $18 MT
Deutsche Bank Downgrades Agilon Health to Hold From Buy, Adjusts Price Target to $12 From $27 MT
Benchmark Adjusts agilon health's Price Target to $22 From $28, Keeps Buy Rating MT
Wells Fargo Adjusts agilon health's Price Target to $16 From $23, Keeps Overweight Rating MT
Goldman Sachs Cuts Price Target on agilon health to $22 From $25, Maintains Buy Rating MT
RBC Cuts Price Target on agilon health to $23 From $28, Keeps Outperform Rating MT
TD Cowen Adjusts agilon health's Price Target to $25 From $29, Keeps Outperform Rating MT
Goldman Sachs Adjusts Price Target on agilon health to $25 From $29, Maintains Buy Rating MT
RBC Cuts Price Target on agilon health to $28 From $33, Maintains Outperform Rating MT
Truist Securities Adjusts Price Target on agilon health to $27 From $35, Maintains Buy Rating MT
Evercore ISI Initiates agilon health at In Lline With $22.50 Price Target MT
Goldman Sachs Adjusts agilon health's Price Target to $29 From $32, Keeps Buy Rating MT
Deutsche Bank Trims agilon health Price Target to $27 From $28, Maintains Buy Rating MT
Stifel Adjusts agilon health's Price Target to $20 From $29, Keeps Buy Rating MT
Truist Securities Adjusts Price Target on Agilon Health to $35 From $29, Keeps Buy Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
5.5 USD
Average target price
8.5 USD
Spread / Average Target
+54.55%
High Price Target
20 USD
Spread / Highest target
+263.64%
Low Price Target
5 USD
Spread / Lowest Target
-9.09%

Consensus detail

Consensus revision (last 18 months)

Analysts covering agilon health, inc.

Citigroup
Barclays
Deutsche Bank Securities
Truist Securities
RBC Capital Markets
TD Cowen
Wolfe Research
JPMorgan Chase
Goldman Sachs
JMP Securities
Benchmark Company
Wells Fargo Securities
Evercore ISI
Stifel Nicolaus
Guggenheim
SVB Securities LLC
BTIG
SVB Leerink
Jefferies & Co.
Cowen
William Blair & Co.
BofA Securities
J.P. Morgan Chase

Ratings for agilon health, inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. AGL Stock
  4. Consensus agilon health, inc.